Cannabinoids to Improve Health-Related Quality of Life in Patients with Neurological or Oncological Disease: A Meta-Analysis
Vera Belgers, J G Röttgering, Linda Douw, Martin Klein, Johannes C. F. Ket, Peter M. van de Ven, Thomas Würdinger, Myra E. van Linde, Johanna M. Niers, Markus Weber, Marcel G. M. Olde Rikkert, José Luis López-Sendón, Óscar Arrieta, Kristina B. Svendsen, Marcos Hortes Nisihara Chagas, Carlos Maurício Oliveira de Almeida, Mathilde C.M. Kouwenhoven, Philip C. De Witt Hamer
Abstract
Background: Cannabinoids have been suggested to alleviate frequently experienced symptoms of reduced mental well-being such as anxiety and depression. Mental well-being is an important subdomain of health-related quality of life (HRQoL). Reducing symptoms and maintaining HRQoL are particularly important in malignant primary brain tumor patients, as treatment options are often noncurative and prognosis remains poor. These patients frequently report unprescribed cannabinoid use, presumably for symptom relieve. As studies on brain tumor patients specifically are lacking, we performed a meta-analysis of the current evidence on cannabinoid efficacy on HRQoL and mental well-being in oncological and neurological patients. Methods: We performed a systematic PubMed, PsychINFO, Embase, and Web of Science search according to PRISMA guidelines on August 2 and 3, 2021. We included randomized controlled trials (RCTs) that assessed the effects of tetrahydrocannabinol (THC) or cannabidiol (CBD) on general HRQoL and mental well-being. Pooled effect sizes were calculated using Hedges g. Risk of bias of included studies was assessed using Cochrane's Risk of Bias tool. Results: We included 17 studies: 4 in oncology and 13 in central nervous system (CNS) disease. Meta-analysis showed no effect of cannabinoids on general HRQoL ( g =−0.02 confidence interval [95% CI −0.11 to 0.06]; p =0.57) or mental well-being ( g =−0.02 [95% CI −0.16 to 0.13]; p =0.81). Conclusions: RCTs in patients with cancer or CNS disease showed no effect of cannabinoids on HRQoL or mental well-being. However, studies were clinically heterogeneous and since many glioma patients currently frequently use cannabinoids, future studies are necessary to evaluate its value in this specific population.